Du Pont has begun the process of weeding out suitors for its medicalproducts business, according to the Wilmington, DE, company. Thefirm is sending out information on its medical products unitsto companies that it believes are qualified to buy the
Du Pont has begun the process of weeding out suitors for its medicalproducts business, according to the Wilmington, DE, company. Thefirm is sending out information on its medical products unitsto companies that it believes are qualified to buy the businesses,according to spokesperson Jayne Seebach Persico.
Industry speculation has run rampant as to the identity of abuyer for the units, which include the Du Pont Diagnostic Imagingfilm and digital imaging business. Some observers have suggestedthat a buyer has already been found, but those pundits are jumpingthe gun, Persico said.
"The field has been narrowed, but we do not have a buyerat this time," Persico said.
We don't anticipate selling or having a firm idea of who thebuyer is until the (Radiological Society of North America meeting).
Du Pont received 60 to 80 inquiries in the weeks after it announcedit was selling the medical products business to pay for the purchaseof its stock held by Seagram (SCAN 6/7/95). The company is determiningwhich of those candidates are qualified to continue in the process,which will require the signing of a confidentiality agreementbefore interested parties can receive additional information onthe medical products business.
Among the criteria Du Pont is using to size up potential buyersare the strategic business fit between Du Pont and the acquiringcompany, whether antitrust issues would interfere with an acquisition,and the company's treatment of employees and customers. Du Ponthopes to have the deal completed by early 1996, Persico said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.